Inhibiting CDK4/6 in Breast Cancer with Palbociclib, Ribociclib, and Abemaciclib: Similarities and Differences
2020/12/28 by C. Louwrens Braal, Elisabeth M. Jongbloed, Saskia M. Wilting +5 · 27 citations
Medicine · #Advanced Breast Cancer Therapies #Chronic Lymphocytic Leukemia Research #Cancer-related Molecular Pathways
paper · pdf · doi:10.1007/s40265-020-01461-2
Abstract
The cyclin-dependent kinase (CDK) 4/6 inhibitors belong to a new class of drugs that interrupt proliferation of malignant cells by inhibiting progression through the cell cycle. Three such inhibitors, palbociclib, ribociclib, and abemaciclib were recently approved for breast cancer treatment in various settings and combination regimens. On the basis of their impressive efficacy, all three CDK4/6 inhibitors now play an important role in the treatment of patients with HR+, HER2- breast cancer; however, their optimal use still needs to be established. The three drugs have many similarities in both pharmacokinetics and pharmacodynamics. However, there are some differences on the basis of which the choice for a particular CDK4/6 inhibitor for an individual patient can be important. In this article, the clinical pharmacokinetic and pharmacodynamic profiles of the three CDK4/6 inhibitors are reviewed and important future directions of the clinical applicability of CDK4/6 inhibitors will be discussed.
Citations
Cited by
- Cell cycle dysregulation in cancer
- Matricellular protein SMOC2 safeguards tubular integrity in acute kidney injury via integrin β3-dependent inhibition of CCND1-CDK4/6 axis
- Thromboembolic Events with Cyclin-Dependent Kinase 4/6 Inhibitors in the FDA Adverse Event Reporting System. [europepmc]
- CDK4/6 Inhibitors in Melanoma: A Comprehensive Review. [europepmc]
- Inhibition of CDK4/6 as Therapeutic Approach for Ovarian Cancer Patients: Current Evidences and Future Perspectives. [europepmc]
- Targeting CDK9 for the Treatment of Glioblastoma. [europepmc]
- Drug-drug interactions between palbociclib and proton pump inhibitors may significantly affect clinical outcome of metastatic breast cancer patients. [europepmc]
- Resistance to CDK4/6 Inhibitors in Estrogen Receptor-Positive Breast Cancer. [europepmc]
- Therapeutic potential of pyrrole and pyrrolidine analogs: an update. [europepmc]
- Identifying Inhibitors of -1 Programmed Ribosomal Frameshifting in a Broad Spectrum of Coronaviruses. [europepmc]
- Cardiotoxicity Induced by Protein Kinase Inhibitors in Patients with Cancer. [europepmc]
- Proton pump inhibitors may reduce the efficacy of ribociclib and palbociclib in metastatic breast cancer patients based on an observational study. [europepmc]
- The Mechanisms of lncRNA-Mediated Multidrug Resistance and the Clinical Application Prospects of lncRNAs in Breast Cancer. [europepmc]
- Cellular senescence and the tumour microenvironment. [europepmc]
- Small-molecule inhibitors, immune checkpoint inhibitors, and more: FDA-approved novel therapeutic drugs for solid tumors from 1991 to 2021. [europepmc]
- Small molecule inhibitors targeting the cancers. [europepmc]
- The Renaissance of CDK Inhibitors in Breast Cancer Therapy: An Update on Clinical Trials and Therapy Resistance. [europepmc]
- The CDK inhibitor AT7519 inhibits human glioblastoma cell growth by inducing apoptosis, pyroptosis and cell cycle arrest. [europepmc]
- Targeting Breast Cancer: An Overlook on Current Strategies. [europepmc]
- Cereblon-Recruiting PROTACs: Will New Drugs Have to Face Old Challenges? [europepmc]
- CDK4/6 inhibitor resistance in estrogen receptor positive breast cancer, a 2023 perspective. [europepmc]
- Abemaciclib, Palbociclib, and Ribociclib in Real-World Data: A Direct Comparison of First-Line Treatment for Endocrine-Receptor-Positive Metastatic Breast Cancer. [europepmc]
- Targeting CDK9 with selective inhibitors or degraders in tumor therapy: an overview of recent developments. [europepmc]
- Therapy-Induced Senescence Contributes to the Efficacy of Abemaciclib in Patients with Dedifferentiated Liposarcoma. [europepmc]
- Discovery of KB-0742, a Potent, Selective, Orally Bioavailable Small Molecule Inhibitor of CDK9 for MYC-Dependent Cancers. [europepmc]
- Revolutionizing cancer care strategies: immunotherapy, gene therapy, and molecular targeted therapy. [europepmc]
- A Review of Approaches to Potentiate the Activity of Temozolomide against Glioblastoma to Overcome Resistance. [europepmc]
Related